|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Net earned premiums | |||||
| Fees and other income | |||||
| Net investment income | |||||
| Net realized losses on investments (including $6.7, $25.1 and $17.0 of impairment-related losses for the years ended December 31, 2025, 2024 and 2023, respectively) and fair value changes to equity securities | |||||
| Total revenues | |||||
| Benefits, losses and expenses | |||||
| Policyholder benefits | |||||
| Underwriting, selling, general and administrative expenses | |||||
| Goodwill impairment (Note 14) | |||||
| Interest expense | |||||
| Loss (gain) on extinguishment of debt (Note 18) | |||||
| Total benefits, losses and expenses | |||||
| Income before income tax expense | |||||
| Income tax expense | |||||
| Net income from continuing operations | |||||
| Net income from discontinued operations (Note 4) | |||||
| Net income | |||||
| Less: Preferred stock dividends | |||||
| Net income attributable to common stockholders, basic | |||||
| Earnings Per Common Share | |||||
| Net income from continuing operations (in dollars per share) | |||||
| Net income from discontinued operations (in dollars per share) | |||||
| Basic (in dollars per share) | |||||
| Net income from discontinuing operations (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Share Data | |||||
| Weighted average common shares outstanding used in basic per common share calculations (in shares) | |||||
| Plus: Dilutive securities (in shares) | |||||
| Weighted average common shares used in diluted per common share calculations (in shares) | |||||
Loading...